AXSM: Axsome Therapeutics Inc Narx-foyda multiplikatori
Axsome Therapeutics (AXSM) atrof-muhit chiqindilarini yo'q qilish bo'yicha qat'iy qoidalarga rioya qilgan holda, markaziy nerv tizimi (CNS) terapiyasi kombinatsiyalariga bo'lgan yuqori talabdan foydalanmoqda. P/E koeffitsiyenti dinamikasi aktivning xavfsizlik zaxirasini baholashga yordam beradi, bunda -44.70 ushbu parametrning qiymatini ko'rsatadi. Kompaniyaning faol R&D loyihalari migren, depressiya va narkolepsiya uchun yangi davolash usullarini tijoratlashtirishni tezlashtirmoqda.
Axsome Therapeutics Inc (AXSM) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- emitentning balans qiymati statistikasi:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Umumiy qarzning xususiy kapitalga nisbati Axsome Therapeutics|AXSM - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati Axsome Corp|AXSM - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Axsome Therapeutics, Inc.|AXSM - Kompaniyaning uzoq muddatli majburiyatlari|Qisqa muddatli majburiyatlar miqdori Axsome Therapeutics|Oraliq qoplash koeffitsiyenti axsome.com
- foyda va bozor multiplikatorlari tafsilotlari:
AXSM - Sof foyda|Kutilayotgan sof foyda Axsome Therapeutics|AXSM - Narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori Axsome|AXSM - PEG multiplikatori|EV/EBITDA multiplikatori Axsome Therapeutics, Inc.|AXSM - Foizlar, soliqlar va eskirish to'lanishidan oldingi foyda|So'nggi 12 oy davomida bitta aksiya uchun foyda Axsome Therapeutics|AXSM - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida yillik hisobda bir aksiya uchun foyda o'sishi axsome.com|AXSM - Bu yil bir aksiya uchun sof foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi Axsome Therapeutics
Kompaniyaning umumiy tahlili:axsome.com - AXSM
P/E koeffitsiyenti sof foydaning har bir birligining bozor qiymatini aks ettiradi va bu kelajakdagi biznes o'sishi uchun to'langan premiumni baholash imkonini beradi. Axsome Therapeutics (AXSM) kompaniyasining forward P/E koeffitsiyentini tahlil qilish orqali investor fundamental qiymatni tebranishlardan ajratadi, bu esa Axsome Therapeutics (AXSM) uchun juda muhimdir, chunki uning ishlab chiqarishni autsorsing qilish modeli kapital xarajatlarini va ekologik xatarlarni minimallashtirib, baholashni faqat neyro-dorilar ishlab chiqish samaradorligiga qaratadi.
Raqobatdosh kompaniyalar
P/E multiplikatori biogen.com|Narx-foyda koeffitsiyenti NBIX (Neurocrine Biosciences, Inc.)|Regencell Bioscience Ltd - Narx-foyda multiplikatori|Narxning foydaga nisbati ACADIA Pharmaceuticals Inc ACAD|Biznesning o‘zini qoplash muddati Xenon Corp (XENE)|VKTX - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati supernus.com|Catalyst Pharmaceuticals, Inc. (CPRX) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Denali|HRMY (Harmony Pharma) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Biohaven Corp BHVN|Narx-foyda koeffitsiyenti AMLX (Amylyx Pharmaceuticals)|TRVI (trevitherapeutics.com) - Kompaniya qiymatining sof foydaga nisbati|Praxis Precision Medicines, Inc. - Narx-foyda koeffitsiyenti|Bozor narxining sof foydaga nisbati AVXL (Anavex)|CeriBell Corp - P/E multiplikatori|Kompaniya qiymatining sof foydaga nisbati PRTA (Prothena Corporation)|ALEC: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati annexonbio.com (ANNX)|Narxning foydaga nisbati Omeros Corp|NGNE: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ACIU|P/E multiplikatori Voyager Corp (VYGR)|Narxning foydaga nisbati Neumora Therapeutics NMRA|SCLX (scilexholding.com) - Kapitalizatsiyaning sof foydaga nisbati|Tevogen Bio - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Alpha Cognition|CGTX (Cognition Therapeutics, Inc.) - Narx-foyda koeffitsiyenti|Inhibikase Pharma (IKT) - P/E multiplikatori|Narx-foyda koeffitsiyenti SAVA|ASRT (Assertio Therapeutics) - Bozor narxining sof foydaga nisbati|P/E multiplikatori COYA|Biznesning o‘zini qoplash muddati vistagen.com|P/E multiplikatori OVID (Ovid Therapeutics)|ABOS - Narx-foyda koeffitsiyenti|CRVO - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Alterity Therapeutics ATHE|CLNN: P/E multiplikatori|PepGen (PEPG) - P/E multiplikatori|Narx-foyda koeffitsiyenti JUNS|Narx-foyda multiplikatori RLMD (Relmada Corp)|Narxning foydaga nisbati Annovis Bio, Inc. (ANVS)|Biznesning o‘zini qoplash muddati gracetx.com|Narxning foydaga nisbati Firefly Neuroscience AIFF|KLTO - Narx-foyda koeffitsiyenti|NRSN - Narxning foydaga nisbati|RVPH (Reviva Pharmaceuticals, Inc.) - Narx-foyda multiplikatori|MTVA: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati neuraxis.com (NRXS)|Narx-foyda koeffitsiyenti HSDT|P/E multiplikatori Passage Bio Corp|Narxning foydaga nisbati Neuphoria Therapeutics Inc. (NEUP)|NERV (Minerva) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Athira Pharma, Inc. ATHA|addextherapeutics.com (ADXN) - Kapitalizatsiyaning foydaga nisbati|Alzamend - P/E multiplikatori|CYCN - P/E multiplikatori|PTIX (protagenic.com) - Narx-foyda koeffitsiyenti|Narx-foyda multiplikatori KTTA|Narxning foydaga nisbati Cortigent Inc|avenuetx.com (ATXI) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati BrainStorm Cell Therapeutics (BCLI)|CARA - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati Chromocell Therapeutics Corporation CHRO|ELYM - Narx-foyda koeffitsiyenti|Intra-Cellular - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati longboardpharma.com|MRNS (Marinus Pharmaceuticals, Inc.) - Narx-foyda koeffitsiyenti|NKGen Biotech Inc - Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti NRBO|SAGE (Sage Therapeutics Inc) - Bozor narxining sof foydaga nisbati|P/E multiplikatori SNPX|TRVN (trevena.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori VIGL (Vigil Neuroscience, Inc.)|anewmeds.com (WENA) - Kapitalizatsiyaning foydaga nisbati|CERE - Narxning foydaga nisbati
